There are 2789 resources available
920P - The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)
Presenter: Simona Guerriero
Session: ePoster Display
921P - Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation
Presenter: VINAYAKUMAR MUTTAGI
Session: ePoster Display
922P - Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Presenter: Michael Pogorzelski
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display
924P - HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany
Presenter: Harald Müller-Huesmann
Session: ePoster Display
926TiP - Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
Presenter: Grzegorz Obara
Session: ePoster Display
928TiP - Induction versus adjuvant gemcitabine/cisplatin in locally advanced non-metastatic nasopharyngeal carcinoma: A randomised phase III trial
Presenter: Shereen Masoud
Session: ePoster Display
929TiP - HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
Presenter: Amanda Psyrri
Session: ePoster Display